Evidence map›Paper›PMID 34904407›Full record

ArticleJournal of Korean medical science2021

Evaluation of Three Multiplex Real-time Reverse Transcription PCR Assays for Simultaneous Detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus in Nasopharyngeal Swabs.

Jiwon Yun, Jae Hyeon Park, Namhee Kim, Eun Youn Roh, Sue Shin, Jong Hyun Yoon, Taek Soo Kim, Hyunwoong Park

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Journal of Korean medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing (December 2023).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Guideline
  2. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Evaluation of the fully automated, sample-to-result Seegene STARlet-AIOS platform for detection of SARS-CoV-2, influenza virus A, influenza virus B, and RSV.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiwon YunDepartment of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-6306-3944
Jae Hyeon ParkDepartment of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-0261-2185
Namhee KimDepartment of Laboratory Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-9851-1727
Eun Youn RohDepartment of Laboratory Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-1787-7509
Sue ShinDepartment of Laboratory Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0003-4791-8671
Jong Hyun YoonDepartment of Laboratory Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-1252-4739
Taek Soo KimDepartment of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-2093-1721
Hyunwoong ParkDepartment of Laboratory Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0001-7765-2259
Seoul National University · KRSeoul National University Hospital · KR

Funding

Seegene
6 · The paper itself

Abstract

backgroundIn the coronavirus disease 2019 (COVID-19) pandemic era, the simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (Flu), and respiratory syncytial virus (RSV) is important in the rapid differential diagnosis in patients with respiratory symptoms. Three multiplex real-time reverse transcription polymerase chain reaction (rRT-PCR) assays have been recently developed commercially in Korea: PowerChek™ SARS-CoV-2, Influenza A&B Multiplex Real-time PCR Kit (PowerChek; KogeneBiotech); STANDARD™ M Flu/SARS-CoV-2 Real-time Detection Kit (STANDARD M; SD BioSensor); and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay (Allplex; Seegene). We evaluated the analytical and clinical performances of these kits.

methodsA limit of detection tests were performed and cross-reactivity analysis was executed using clinical respiratory samples. Ninety-seven SARS-CoV-2-positive, 201 SARS-CoV-2-negative, 71 influenza A-positive, 50 influenza B-positive, 78 RSV-positive, and 207 other respiratory virus-positive nasopharyngeal swabs were tested using the three assays. The AdvanSure™ respiratory viruses rRT-PCR assay (AdvanSure; LG Life Sciences) was used as a comparator assay for RSV.

resultsExcept in influenza B, in SARS-CoV-2 and influenza A, there were no significant differences in detecting specific genes of the viruses among the three assays. All three kits did not cross-react with common respiratory viruses. All three kits had greater than 92% positive percent agreement and negative percent agreement and ≥ 0.95 kappa value in the detection of SARS-CoV-2 and flu A/B. Allplex detected RSV more sensitively than AdvanSure.

conclusionThe overall performance of three multiplex rRT-PCR assays for the concurrent detection of SARS-CoV-2, influenza A/B, and RSV was comparable. These kits will promote prompt differential diagnosis of COVID-19, influenza, and RSV infection in the COVID-19 pandemic era.

Indexed as

COVID-19Cross ReactionsHumansInfluenza A virusInfluenza B virusInfluenza, HumanLimit of DetectionMultiplex Polymerase Chain ReactionNasopharynxNucleocapsid ProteinsPolyproteinsReagent Kits, DiagnosticRepublic of KoreaRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRNA, ViralM1 protein, Influenza A virusNucleocapsid Proteinsnucleoprotein, influenza B virusORF1ab polyprotein, SARS-CoV-2PolyproteinsReagent Kits, DiagnosticRNA, ViralViral Matrix ProteinsViral ProteinsInfluenza A VirusInfluenza B VirusMultiplex Polymerase Chain ReactionRespiratory Syncytial VirusesSARS-CoV-2

Identifiers

PMID34904407
PMCPMC8668494
OpenAlexW3215644133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.